Harmony Biosciences Holdings (HRMY) Short term Debt (2021 - 2026)

Harmony Biosciences Holdings (HRMY) has 6 years of Short term Debt data on file, last reported at $20.0 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt rose 14.29% year-over-year to $20.0 million; the trailing twelve-month figure through Mar 2026 stood at $20.0 million (up 14.29% YoY), and the FY2025 full-year result was $20.0 million, up 23.08% from the prior year.
• Short term Debt held at $20.0 million in Q1 2026, from $20.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $20.0 million in Q3 2025 to a low of $2.0 million in Q1 2022.
• A 5-year average of $12.5 million and a median of $15.0 million in 2023 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt changed 0.0% in 2022 and jumped 650.0% in 2023, its largest moves.
• Tracing HRMY's Short term Debt over 5 years: stood at $2.0 million in 2022, then jumped by 650.0% to $15.0 million in 2023, then rose by 8.33% to $16.2 million in 2024, then increased by 23.08% to $20.0 million in 2025, then changed by 0.0% to $20.0 million in 2026.
• Business Quant data shows HRMY's Short term Debt at $20.0 million in Q1 2026, $20.0 million in Q4 2025, and $20.0 million in Q3 2025.